# Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron Deficiency

> **NCT03181451** · PHASE1 · COMPLETED · sponsor: **Shield Therapeutics** · enrollment: 37 (actual)

## Conditions studied

- Iron Deficiency, Anaemia in Children
- Iron-Deficiency

## Interventions

- **DRUG:** Ferric Maltol

## Key facts

- **NCT ID:** NCT03181451
- **Lead sponsor:** Shield Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-14
- **Primary completion:** 2018-03-28
- **Final completion:** 2018-03-28
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2021-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03181451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03181451, "Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron Deficiency". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03181451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*